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Bison (Bison bison) and elk (Cervus elaphus nelsoni) in the Greater Yellowstone Area
(GYA), USA, are infected with Brucella abortus, the causative agent of bovine brucellosis, and they
serve as a wildlife reservoir for the disease. Bovine brucellosis recently has been transmitted from
infected elk to cattle in Montana, Wyoming, and Idaho and has resulted in their loss of brucellosisfree status. An efficacious Brucella vaccine with a delivery system suitable for wildlife would be a
valuable tool in a disease prevention and control program. We evaluated Strain 19 (S19) in a
sustained release vehicle consisting of alginate microspheres containing live vaccine. In a challenge
study using red deer (Cervus elaphus elaphus) as a model for elk, alginate, a naturally occurring
polymer combined with a protein of Fasciola hepatica vitelline protein B was used to
microencapsulate S19. Red deer were orally or subcutaneously immunized with 1.531010
colony-forming units (CFUs) using microencapsulated S19. Humoral and cellular profiles were
analyzed bimonthly throughout the study. The vaccinated red deer and nonvaccinated controls
were challenged 1 yr postimmunization conjunctivally with 13109 CFUs of B. abortus strain 2308.
Red deer vaccinated with oral microencapsulated S19 had a statistically significant lower bacterial
tissue load compared with controls. These data indicate for the first time that protection against
Brucella-challenge can be achieved by combining a commonly used vaccine with a novel oral
delivery system such as alginate-vitelline protein B microencapsulation. This system is a potential
improvement for efficacious Brucella-vaccine delivery to wildlife in the GYA.
Key words: Brucella abortus, brucellosis, Cervus elaphus, encapsulation, red deer, vaccine.
ABSTRACT:

INTRODUCTION

Brucella abortus, a facultative intracellular gram-negative bacterium, is the
etiologic agent of bovine brucellosis,
which is also a zoonotic disease of nearly
worldwide distribution (Boschiroli et al.,
2001).The bacterium is mainly transmitted
from infected animals to other animals
and humans through contact with contaminated animal tissues, excretions, and
secretions (Corbel, 1997). Human brucellosis (undulant fever) can be a severe and
debilitating disease requiring prolonged
treatment and often leaving permanent
sequelae (Pappas et al., 2005). Moreover,
brucellosis is a major cause of direct and
indirect economic losses for livestock
industries.

In the United States, B. abortus has
been largely eradicated in cattle, but it
continues to be a problem in bison (Bison
bison) and elk (Cervus elaphus nelsoni) in
the Greater Yellowstone Area (GYA), USA
(Davis and Elzer, 2002). The prevalence
of brucellosis within these wildlife populations constitutes a health problem mainly because of the threat of free-ranging
wildlife transmitting bovine brucellosis to
cattle and possibly to humans. Within the
past few years, several B. abortus-infected
cattle herds have been identified in
Wyoming, Idaho (Holland, unpublished),
and Montana (Cross et al., 2007) in which
the source of the infection was presumed
to be bison or elk (Holland, 2004). The
continued prevalence of B. abortus in the
GYA and surrounding states can, in large
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We have investigated the possibility of
delivering the currently licensed vaccine
S19 in a controlled microencapsulated
format. We have demonstrated previously
an increased efficacy when live Brucella
vaccine candidates are delivered in microspheres containing alginate, a naturally
occurring biopolymer combined with vitelline protein B (VpB) of the sheep liver
fluke, Fasciola hepatica. This protein
possess an unusual enzymatic resistance
to breakdown, modifying the erosion time
of the capsule content (Arenas-Gamboa et
al., 2008). In the present study, we
evaluated the vaccine efficacy of S19 when
delivered by oral or subcutaneous routes.
MATERIALS AND METHODS
Animals

Fifty-four 1- to 2-yr-old female red deer
(Cervus elaphus elaphus) were bought from a
privately owned tuberculosis- and brucellosisfree herd. This species was chosen as an
animal model for Rocky Mountain elk (Cervus
elaphus nelsoni) because of its close genetic
relationship, ease of handling, and animal
husbandry. Upon arrival, animals were retested for anti-Brucella immunoglobulin G (IgG)
levels (total IgG) by enzyme-linked immunosorbent assay (ELISA), dewormed (using
Moxidectin and Cydectin, Wyeth, Madison,
Wisconsin, USA), and allowed to acclimate for
3 mo. For experimental purposes, the red deer
were randomly assigned into six treatment
groups (n59). All animal care and experimental procedures were performed in compliance
with institutional animal care and guidelines as
required at Texas A&M University.
B. abortus S19 and strain 2308 cultures

Bacteria used in these experiments include
B. abortus S19 used as the vaccine and B.
abortus virulent strain 2308. Brucella was
grown on tryptic soy agar (TSA) plates
incubated at 37 C in atmosphere containing
5% (w/v) CO2 for 72 hr. Bacteria were
harvested by scraping off of the plate surface
into phosphate-buffered saline (PBS). The
harvested bacteria were pelleted by centrifugation at 3,000 3 G, and the pellet was
resuspended in fresh PBS. This step was
repeated two more times and the concentration of bacteria was determined by optical
density using a standardized curve of optical
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part, be attributed to the wildlife management practices of supplemental feeding
implemented during the winter. The
winter feed grounds in the GYA have
resulted in significant over congregations
of elk and increased the risk of intraspecific and interspecific transmission of B.
abortus (Davis and Elzer, 2002).
Current vaccine strains used to control
brucellosis in cattle have proven to be less
effective in wildlife. Data from controlled
experiments suggest that Strain 19 (S19)
prevents abortion in only 30% of immunized elk (Davis and Elzer, 2002), whereas
RB51, when given in conventional format,
is ineffective in elk (Thorne et al., 1980;
Kreeger et al., 2002a; Cook et al., 2002),
and of significantly reduced efficacy in
bison (Davis and Elzer, 2002). Reduced
efficacy of the vaccine strains arises from
difficulties with vaccination of wildlife
species but also from the delivery method
used to immunize the animals. Although
the efficacy of S19 in elk is not comparable
with its performance in cattle, S19 has
been used since 1985 in Wyoming elk, and
it is presently the only available alternative. The method used to immunize elk in
Wyoming is by remote ballistic injections
of biodegradable hollow pellets containing
lyophilized S19 from distances of up to
30 m (Olsen et al., 2006). Issues associated
with this technique include excessive time,
labor, logistics, and elevated cost as well as
inconsistencies in injection site, route of
injection, and amount of vaccine delivered.
It is generally acknowledged that the
removal of winter feeding is not a viable
strategy for the short-term prevention and
control of brucellosis in wildlife in the
GYA. Alternative prevention and control
measures such as improvement of vaccine
efficacy and more suitable techniques to
deliver vaccines to free-ranging wildlife
need further investigation not only to
reduce the prevalence of brucellosis in
wildlife but also to reduce the risk of
transmission from infected wildlife to
cattle and possibly humans.
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density (Klett units) vs. colony-forming units
(CFUs). The concentration of viable organisms was verified retrospectively by plating
serial dilutions of cell suspensions.
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encapsulated S19 without VpB (oral), or 4)
encapsulated S19 with alginate and VpB (oral).
Control groups received 1.531010 CFUs of
either 1) nonencapsulated S19 (SC) or 2) empty
capsules (no bacteria entrapped) (SC).

Preparation of B. abortus S19-loaded microspheres

Bacterial enumeration and viability

To determine the bacterial content per
milliliter of alginate particles, 1 ml of capsules
was removed from the encapsulator before
permanent cross-linking with poly-L-lysine or
VpB with poly-L-lysine. The capsules were
allowed to settle and washed twice with MOPS
buffer, and then particles were dissolved using
1 ml of depolymerization solution (50 mM
Na3-citrate, 0.45% NaCl, and 10 mM MOPS,
pH 7.2) with stirring for 10 min. Bacterial
number (colony-forming units per milliliter)
per milliliter of capsules was determined by
plating onto TSA plates.
Immunization of red deer

Red deer were randomly distributed into six
treatment groups (n59). Animals were given a
single dose of vaccine containing either 1)
encapsulated S19 without VpB (SC), 2) encapsulated S19 with alginate and VpB (SC), 3)

Detection of Brucella-specific antibody levels

To determine the level of anti-Brucellaspecific antibody in serum, blood samples
were collected by jugular venipuncture immediately before vaccination, and 6, 12, and 17
days postvaccination. Serum samples were
evaluated for total IgG by ELISA. Heat-killed
and sonicated B. abortus 2308 lysate was used
as antigen to coat 96-well plates (NuncImmuno plates, high binding protein, Nalge
Nunc International, Rochester, New York,
USA) at a protein concentration of 25 mg/well.
After overnight incubation at 4 C, plates were
washed with PBS containing 0.05% (w/v)
Tween 20 and blocked in the same solution
supplemented with 0.25% (w/v) bovine serum
albumin to prevent nonspecific binding. The
blocking buffer was removed, and deer serum
samples diluted 1:100 in blocking buffer were
incubated 2 hr at room temperature with
rocking. After three more washes, horseradish
peroxidase-conjugated goat anti-deer IgG
(Kirkegaard and Perry Laboratories, Gaithersburg, Maryland, USA) was added to the wells
at a dilution 1:1,000 and incubated at room
temperature for 1 hr. After incubation, plates
were washed as described above, and the
peroxidase substrate o-phenylenediamine dihydrochloride (Sigma-Aldrich, St. Louis, Missouri, USA) was added following the manufacturer’s instructions and incubated for no
more than 20 min. The reaction was stopped
by the addition of 50 ml of 0.5 M NaOH, and
the absorbance measured at 450 nm (A450). All
assays were performed in triplicate and
repeated at least two times.
Lymphocyte proliferation assay from peripheral
blood mononuclear cells

At 17 wk postvaccination, mononuclear cells
were isolated from the buffy coats of peripheral
blood as described previously, with some
modifications (Waters et al., 2002). In brief,
23105 cells/well were seeded in 96-well plates
(Falcon, BD Biosciences, San Jose, California,
USA) in RPMI medium containing 10% (v/v)
fetal bovine serum, 1 mM L-glutamine, and
1 mM nonessential amino acids. Cells were
stimulated with 1) B. abortus S2308 (wild-type)
lysate at a concentration of 12.5 mg/ml, 2)
concanavalin A (5 mg/ml), or 3) medium alone
during incubation for 6 days at 37 C in
atmosphere containing 5% (v/v) CO2. After
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Alginate beads loaded with 1.531010 CFUs/
ml of the vaccine strain S19 were prepared as
described previously for live bacteria (Abraham et al., 1996), with several modifications.
In brief, enumerated live S19 vaccine strain
(total 1.531011 for 10 doses) was resuspended
in a total of 100 ml of 3-[N-morpholino]
propanesulfonic acid (MOPS) buffer (10 mM
MOPS and 0.85% NaCl, pH 7.4) and mixed
with 10 ml of alginate solution (1.5% sodium
alginate, 10 mM MOPS, and 0.85% NaCl,
pH 7.3). Three-hundred-micrometer spheres
were obtained by extruding the suspension
through a 200-mm nozzle into a 100 mM
calcium chloride solution and stirred for
15 min using the Inotech encapsulator I-50
(Inotech Biosystems International, Rockville,
Maryland, USA). To permanently cross-link
the capsule, microspheres were resuspended
in MOPS buffer supplemented with 0.05% (w/
v) poly-L-lysine (molecular weight 22,000) for
15 min. After two successive washes, the
beads were washed with stirring to a MOPS
buffer supplemented with 0.03% (w/v) alginate for 5 min to apply a final outer coating.
The addition of VpB as a component of the
alginate core was achieved by adding 1 mg of
VpB to the bacteria-alginate suspension. All
capsules were stored at 4 C in MOPS buffer
until use.
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incubation, 1 mCi of methyl-[3H]thymine was
added to each well, and incubation was
continued for an additional 18 hr. The cells
were harvested onto glass fiber filters using a
96-well plate cell harvester, and the incorporated [3H]thymidine was determined using a
liquid scintillation counter (Beckman Coulter,
Fullerton, California, USA). Data are represented as mean counts per minute (cpm) 6 SD.

One year postvaccination, two to three
animals from each group were housed in
BL3-facility buildings (five to six animals per
building) and acclimated for 2 wk before
challenge. Animals were exposed conjunctivally
using a challenge dose of 13109 CFU/deer of
B. abortus wild-type 2308 as confirmed by
plating serial dilutions onto TSA plates. Two
weeks postchallenge, animals were euthanized,
and spleens, lungs, and liver were harvested,
weighed, and homogenized in 1 ml of peptone
saline per gram of tissue for 5–10 min using a
stomacher. In addition, submandibular, mesenteric, and mammary lymph nodes were
extracted, and each lymph node was homogenized in 1 ml of peptone saline. One hundredmicroliter portions of each sample were serially
diluted and plated in duplicate onto Farrell’s
media (TSA supplemented with 10% [v/v]
horse serum, 2% [w/v] dextrose, and Oxoid
Brucella supplement [Oxoid, Wesel, Germany]). Three to 5 days postinoculation,
bacterial counts were enumerated. Results are
represented as the mean6SEM CFUS/g tissue.
For lymph nodes, results are represented as the
mean6SEM CFUs/lymph node.
Statistical procedures

Immunoglobulin G levels elicited by vaccination are expressed as the mean6SD A450 for
each group. For determination of cellular
responses, cpm from each group is expressed
as the mean6SD cpm. Efficacy of vaccination
was expressed as mean6SEM log CFUs for
each group. The significance of differences
between groups was determined by analysis of
variance using Prism software (GraphPad
Software Inc., San Diego, California, USA).
A P value ,0.05 is considered statistically
significant.
RESULTS
Encapsulated S19 elicited Brucella-specific
IgG responses

Serum collected at different times
postvaccination was assayed for Brucella-

Encapsulated S19 enhances cellular
immune responses

To determine the possible effect of
encapsulation on the cellular response
elicited in red deer vaccinated with S19,
a cellular proliferation assay was performed. Animals were bled 17 wk postvaccination, and blastogenesis was performed using cells isolated from the buffy
coat. Only animals receiving the encapsulated vaccine in which VpB was added to
the core formulation via a subcutaneous
route exhibited statistically significant
proliferative responses compared with
naı̈ve animals (P,0.05). Animals receiving
nonencapsulated vaccine failed to mount
significant cellular responses (Fig. 2).
Evaluation of immune protection provided by
encapsulated B. abortus S19

To determine the effect of encapsulation on immunization, the level of protection provided by vaccination with either
encapsulated or nonencapsulated S19 was
evaluated against wild-type challenge at
1 yr postvaccination. Recovery of challenge organism in spleen, lung, liver, and
submandibular, mesenteric, and mammary lymph nodes was evaluated. Two weeks
postchallenge, only red deer vaccinated
orally with the encapsulated vaccine containing VpB in the formulation had a
statistically significant lower bacterial load
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Challenge and efficacy of vaccination

specific antibodies by ELISA. Immunization with S19 elicited an IgG response in
subcutaneously vaccinated animals that
was significantly different from naı̈ve animals by 6 wk postvaccination (P,0.005).
Animals that received the oral vaccine
elicited lower detectable IgG levels at all
time points, but only animals that received
the oral vaccine with VpB in the formulation had increasing levels of IgG. The IgG
peak in red deer that received this formulation was delayed up to 17 wk postvaccination, indicating a delayed release compared with all of the other groups, for
which IgG peaked at 6 wk postvaccination
(Fig. 1).

ARENAS-GAMBOA ET AL.—ORAL VACCINATION AGAINST BRUCELLA IN RED DEER

in the spleen relative to naı̈ve deer.
Animals vaccinated using this formulation
had a 1.85-log lower (P,0.0005) bacterial
burden (Fig. 3A) compared with naı̈ve
animals. Colonization of wild-type 2308
in lung and liver was not significantly
different between the control and the
immunized groups, but animals that received the encapsulated oral vaccine with
VpB had a lower bacterial burden
(P.0.05; Fig 3B, C). Submandibular
lymph nodes that were closer to the site
of inoculation exhibited the highest CFU
counts compared with the other sites
(Fig. 4A–C). In accordance to the reduced
recovery of wild-type organism in the
spleen, only the oral vaccinees that
received the encapsulated vaccine with
VpB had a significantly lower bacterial

FIGURE 2. Lymphocyte proliferative responses of
peripheral blood mononuclear cells from deer
immunized with S19. Red deer (n59) were vaccinated subcutaneously or orally with 1.531010 colonyforming units of 1) unencapsulated Brucella abortus
S19, 2) encapsulated B. abortus S19 without vitelline
protein B (VpB), 3) encapsulated B. abortus with
VpB, 4) encapsulated oral S19 without VpB, 5)
encapsulated oral S19 with VpB, 6) empty capsules
(control), and 7) positive control (concanavalin A
stimulation). Twelve weeks postvaccination, peripheral blood mononuclear cells were isolated, cultured
at 37 C for 6 days, and pulsed for 18 hr with 1 mCi of
methyl-[3H]thymine. Results are expressed as mean
counts per minute6SD. *Value is statistically different from the control by analysis of variance (P,0.05).

burden in the submandibular lymph nodes
(P,0.005; Fig. 4A).
DISCUSSION

Wildlife vaccination represents a practical tool for the control of transmissible
diseases that represent a health risk to
livestock or humans. Common issues with
vaccines for wildlife include the need for
good protective immunity, minimization of
side effects, safety, ease of handling and
administration, and a low cost of production and delivery. Current vaccination
strategies used to control brucellosis in
the GYA do not fulfill these requirements:
B. abortus S19 vaccine only confers
protection in 30% of elk; it can produce
abortion in a low percentage of vaccinated
animals; and it is ballistically delivered,
increasing the cost and risk of administra-
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FIGURE 1. Immunoglobulin G (IgG) anti-Brucella antibodies in serum from deer vaccinated with
vaccine strain 19 (S19). Red deer (n59) were
vaccinated subcutaneously (SC) or orally with
1.531010 colony-forming units of 1) unencapsulated
Brucella abortus S19, 2) encapsulated B. abortus S19
without vitelline protein B (VpB), 3) encapsulated B.
abortus with VpB, 4) encapsulated oral S19 without
VpB, 5) encapsulated oral S19 with VpB, or 6) empty
capsules (control). Serum samples collected 0, 6, 12,
and 17 wk postvaccination were analyzed for IgG by
enzyme-linked immunosorbent assay. Results are
shown as means6SD of absorbance (OD5optical
density) at 450 nm. *Values are statistically different
(P,0.005) from the control by analysis of variance at
each time point (S19/alginate SC S19/alginate vpB
SC, S19 SC). Closed squares 5 S19/alginate oral;
open squares 5 control nonvaccinated; open triangles 5 S19/alginate/VpB oral; closed triangles 5 S19/
alginate SC; open circles 5 S19/alginate/VpB SC;
closed circles 5 S19 SC.
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FIGURE 3. Vaccination efficacy against 2308
wild-type challenge. Red deer were vaccinated
subcutaneously or orally with 1.531010 colonyforming units (CFUs) of 1) unencapsulated Brucella
abortus S19, 2) encapsulated B. abortus S19 without
vitelline protein B (VpB), 3) encapsulated B. abortus

with VpB, 4) encapsulated oral S19 without VpB, 5)
encapsulated oral S19 with VpB, or 6) empty
capsules (control). One year postvaccination animals
were conjunctivally infected with 13109 CFUs of
wild-type 2308. Two weeks postinfection, animals
were euthanized; spleens were harvested; and the
bacterial count per gram of A) spleen, B) liver, and
C) lung was determined. Values are reported as the
mean log10 recovery of 2308 from the organs.
Difference in colonization between the vaccinated
and control was determined by analysis of variance.
**Value significantly different from control (P,0.01).
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tion. By using microencapsulation techniques, we studied the ability to enhance
S19 efficacy and provide an easier method
to administer the vaccine to wildlife such
as elk.
Experimental evidence suggests that
live vaccines are more efficacious against
brucellosis than killed vaccines (Schurig et
al., 2002; Ko, 2003). Vaccination results
using B. abortus S19 and RB51 and
challenge with 2308 suggest that the
persistence of the Brucella vaccine strain
is also critical to confer protection (Ko,
2003; Kahl-McDonagh et al., 2006). These
two observations have to be taken into
consideration when designing new vaccines or vaccination strategies. In this
study, we were able to develop a method
of vaccine delivery in which the viability of
the bacteria is not compromised by the
encapsulation process (Arenas-Gamboa et
al., 2008). Also, we tested the ability of the
vaccine to protect against virulent 2308
when the immunogen is given by an oral
route. Oral administration was analyzed
because the most cost-effective method of
vaccinating wildlife would be to incorporate the vaccine into an oral bait.
Correlates of humoral immunity were
monitored in all S19 vaccine formulations
and routes of vaccination. Immunization
with S19 induced remarkable IgG levels
even when the vaccine was given in a
microencapsulated format (Fig. 1). Animals that received VpB in the formulation
orally mounted higher IgG levels than red
deer not receiving VpB in the formulation.

ARENAS-GAMBOA ET AL.—ORAL VACCINATION AGAINST BRUCELLA IN RED DEER

1027

r

FIGURE 4. Bacterial dissemination after conjunctival 2308 wild-type challenge. Red deer were
vaccinated subcutaneously or orally with 1.531010
colony-forming units (CFUs) of 1) unencapsulated
Brucella abortus S19, 2) encapsulated B. abortus S19
without vitelline protein B (VpB), 3) encapsulated B.

abortus with VpB, 4) encapsulated oral S19 without
VpB, 5) encapsulated oral S19 with VpB, or 6) empty
capsules (control). One year postvaccination, animals
were conjunctivally infected with 13109 CFUs of
wild-type 2308. Two weeks postinfection, animals
were euthanized; lymph nodes were harvested; and
the bacterial count per lymph node A) submandibular, B) mammary, and C) mesenteric was determined. Values are reported as the mean log10
recovery of 2308 from the different lymph nodes.
Significance of difference in colonization between
the vaccinated and control was determined by
analysis of variance. *Value significantly different
from control (P,0.05).
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This greater IgG response may reflect the
resistance of capsules with VpB to proteolytic breakdown in the stomach. (Rice
Ficht et al., 1992).
Previous investigations suggest that
induction of specific cellular-mediated
immune responses after immunization is
important for the establishment of a
protective immune response in elk (Cook
et al., 2002; Olsen et al., 2006). Studies
performed with the encapsulated S19
indicated that by 17 wk, only alginate/
VpB capsules administered subcutaneously were able to stimulate a statistically
significantly higher cellular response compared with naı̈ve animals. Red deer that
received the same formulation orally did
show enhanced cellular responses, but
these were not statistically significant
(P,0.1). These data suggest that by
incorporating the S19 vaccine into microcapsules, conditions necessary to trigger a
cellular response were provided. Further
studies adjusting the VpB concentration
for the oral formulation are needed to
obtain the response observed with subcutaneous vaccination.
To determine the degree of protection
against virulent 2308 challenge, two to
three animals from each group were
housed in large animal BL-3 facility
buildings. Because of federal regulations
and difficulty in housing these animals,
group sizes were very limited. Among
animals exposed to a conjunctival dose of
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exposure of elk to B. abortus in the field. If
the field is less severe, protection against
field challenge may be greater than
observed in this experimental challenge
study. Further studies to address the
effect of multiple doses of vaccine and
different challenge doses with higher
animal numbers are underway.
In conclusion, a novel method of
vaccination was examined using a controlled release mechanism. Collectively,
our preliminary data demonstrate that oral
vaccination of red deer via alginate-VpB
encapsulation of S19 is a robust and
efficient way to induce protective immune
responses in red deer. We were able to
observe that protection against 2308
virulent challenge was sustained for at
least 1 yr postvaccination. This methodology of vaccination might be a safe and
effective means of preventing and controlling brucellosis in the GYA and may
represent an alternative to enhance the
efficacy of other vaccines that are currently in use.
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13109 CFUs of wild-type 2308, the
highest bacterial burden was observed
from spleens and parotid lymph nodes.
This finding was expected due to the
proximity of these lymph nodes to the site
of inoculation. When vaccination efficacy
was analyzed based on CFU reduction in
spleen of immunized vs. naı̈ve but challenged deer, only animals that received
the vaccine orally within capsules containing VpB in the formulation exhibited
a significant (P,0.005) degree of protection compared with the control. In
accordance with this observation, this
group also exhibited the lowest numbers
of recoverable bacteria in lungs and
livers. Bacterial numbers in the submandibular lymph nodes also were diminished (P,0.005). These results suggest
the induction of mucosal immunity by the
oral vaccine. Further experiments to
determine the induction of mucosal
immunity as well as cytokine production
by alginate microspheres in red deer are
underway.
Prevention of loss of S19 viability inside
the stomach is one of the most critical
steps toward the development of good
mucosal immunity by oral vaccination.
Because the microencapsulated oral vaccine elicited stronger immune responses
than nonencapsulated vaccine, we suggest
that the alginate-VpB formulation protected the vaccine from the harsh enzymatic
environment encountered in the stomach.
This correlates with observations made by
other groups, in which alginate was proven
to resist low pH degradation (Wee and
Gombotz, 1998). The exact mechanism of
protection and delivery remains to be
determined. These results are promising
for the development of an oral bait
vaccine.
This study was conducted over a year,
and animals were vaccinated only once. If
the vaccine is given as oral bait, animals
may be naturally boosted by consuming
multiple doses, thus enhancing vaccine
efficacy. Also, the conjunctival dose used
for challenge may be higher than natural
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